Articles from Noetik

Noetik, an AI-native biotech company pioneering self-supervised machine learning and high-throughput spatial data to develop next-generation cancer therapeutics, announced today a five-year strategic collaboration and AI model licensing agreement with GSK.

Noetik, an AI-native biotech company leveraging self-supervised machine learning and high-throughput spatial data to develop next-generation cancer therapeutics, announced today the appointment of five distinguished scientific leaders, Dr. Vijay Kuchroo, Dr. Matthew Albert, Dr. William Grossman, Dr. Marcia Belvin, and Dr. Kwok-Kin Wong, to its Scientific Advisory Board.

Noetik, an AI-native biotechnology company leveraging advanced machine learning and proprietary data to discover and develop precision cancer therapies, today announced the appointment of Emily Corse, Ph.D. as Executive Vice President, Therapeutics. In this role, Dr. Corse will oversee Noetik’s therapeutics pipeline from discovery through translational development and into early clinical execution.

Noetik, an AI-native biotech company leveraging self-supervised machine learning and high-throughput spatial data to develop next-generation cancer therapeutics, announced today a technical report featuring OCTO-VirtualCell (OCTO-vc) – an AI model capable of inferring the behavior of cells and cell systems in the context of health and disease. Users can preview the model using Celleporter, an interactive tool that enables users to view virtual cell simulations using different prompts across discrete spatial locations in real or virtual patient tissues.

Noetik, an AI-native biotech company leveraging self-supervised machine learning and high-throughput spatial data to develop next-generation cancer therapeutics, announced today the first two presentations of its AI-enabled drug discovery platform at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The posters showcase Noetik’s OCTO foundation model of cell and tissue biology and demonstrate for the first time the application of OCTO to therapeutics discovery.

NOETIK, an AI-native biotech company leveraging self-supervised machine learning and high-throughput spatial data to develop next-generation cancer therapeutics, announced today that it has been selected for the second cohort of the AWS Generative AI Accelerator. Launched by Amazon Web Services, Inc. (AWS), the AWS Generative AI Accelerator identifies top early-stage startups that are using generative AI to solve complex challenges and help them scale and grow. Participants will access AWS credits, mentorship, and learning resources to further their use of artificial intelligence (AI) and machine learning (ML) technologies and grow their businesses.

Noetik, an AI-native biotech company leveraging self-supervised machine learning and high-throughput spatial data to develop next-generation cancer therapeutics, announced today that it closed an oversubscribed $40 million Series A financing round.

Noetik, an AI-native biotechnology company leveraging advanced machine learning and proprietary data to discover and develop precision cancer immunotherapies announces the appointment of Dr. Shafique Virani as Chief Business Officer. Dr. Virani brings a rich background in both business development and clinical development, with experience building therapeutics portfolios at large global organizations, and securing transformational partnerships at innovative biotech organizations. His deep strategic expertise will be critical in driving multiple unique and diverse paths of value generation from Noetik’s innovative platform.

Noetik, an AI-native biotechnology company leveraging advanced machine learning and proprietary data to discover and develop precision cancer immunotherapies announces the pairing of their multimodal human data atlas with an innovative in vivo functional genomics platform to power the development of precision cancer immunotherapies. The platform builds on Perturb-map, a groundbreaking spatial functional genomics technology that allows pooled parallel analysis of hundreds of genetically modified tumor clones in a single experiment. Noetik’s platform will evaluate the impact of genetic variants at an unprecedented in vivo scale. The company is currently generating an initial dataset of >650 mutations in a preclinical model of lung cancer, including pharmacological perturbations.

Noetik, an AI drug discovery company leveraging machine learning and proprietary human data to develop precision therapeutics in immuno-oncology, announced today that it closed an oversubscribed $14M seed financing round led by DCVC, with participation from Zetta Venture Partners, 11.2 Capital, Catalio Capital Management, Epic Ventures, Intermountain Ventures, North South Ventures, Chau Khuong and CJNV BioVentures, Enveda Founder and CEO, Viswa Colluru and Hummingbird Nomads Fund, and Recursion CEO & CFO, Chris Gibson and Michael Secora.